Modeling and Simulation - PK/PD Archives

Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

CertaraMarch 11, 2026

Webinar

What is new in Phoenix 8.8?

Danielle PillsburyMarch 9, 2026

Webinar

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

CertaraMarch 9, 2026

Guide

Navigate GxP Compliance in the Cloud with Confidence

Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…

CertaraMarch 6, 2026

Blog Knowledge Base

Understanding and Calculating Steady State Pharmacokinetics

Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…

CertaraMarch 5, 2026

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle PillsburyMarch 4, 2026

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

Live Events

Phoenix Roadshow 2026 – Cambridge

CertaraMarch 2, 2026

Live Events

Phoenix Roadshow 2026 – Raleigh/Durham

CertaraMarch 2, 2026

Blog

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

CertaraFebruary 27, 2026

Modeling and Simulation – PK/PD

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

What is new in Phoenix 8.8?

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

Navigate GxP Compliance in the Cloud with Confidence

Understanding and Calculating Steady State Pharmacokinetics

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Phoenix Roadshow 2026 – Cambridge

Phoenix Roadshow 2026 – Raleigh/Durham

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

Newsletter sign up

Quick links

Solutions

Contact